Nuwellis generated modest revenue growth in Q4 2025 driven by higher console sales and improved pricing, which also lifted gross margin. However, the company continued to operate at a loss as operating expenses exceeded gross profit while maintaining a limited cash position.

Nuwellis posted a net income in Q3 2025, supported by increased U.S. console sales and consumable utilization. Despite a slight year-over-year revenue decline, operational progress and product launches supported a strong sequential recovery.

Nuwellis generated $1.7 million in revenue during Q2 2025, down from $2.2 million YoY due to a temporary vendor issue. Gross margin declined to 55.5%. The company posted a net loss of $12.6 million and an operating loss of $2.9 million. Cash and cash equivalents stood at $4.45 million as of quarter-end.

Nuwellis reported a 3% increase in revenue and significant improvement in operating loss for Q1 2025. Strategic cost reductions and increased reimbursement positioning supported continued momentum in both pediatric and outpatient segments.

Nuwellis reported Q4 2024 revenue of $2.3 million, a 9% decline compared to the prior year. The company posted a net loss of $1.5 million, or $0.44 per share, with a 25% reduction in total operating expenses. The critical care segment saw revenue growth of 35%, while gross margin improved to 58.4%. Cash and cash equivalents stood at $5.1 million at year-end.

Nuwellis, Inc. reported third quarter 2024 financial results with a revenue of $2.4 million. The company achieved a gross margin of 70% and reduced total operating costs by 30% compared to the prior-year quarter. Net income attributable to common shareholders was $2.4 million, primarily due to the revaluation of a prior period warrant liability.

Nuwellis, Inc. reported a 6% increase in revenue to $2.2 million for the second quarter of 2024, driven by a 30% increase in heart failure and critical care consumables utilization. The company's gross margin improved to 67.2%, and operating expenses decreased by 38%. However, the company reported a net loss of $7.7 million, or $18.85 per share.

Nuwellis, Inc. reported a 2% increase in revenue for the first quarter of 2024, driven by an 11% increase in consumable sales. The company's gross margin improved to 64.1% compared to 58.4% in the prior year period. Operating loss decreased due to cost-saving measures.

Nuwellis, Inc. reported a 9% increase in revenue for the fourth quarter of 2023, reaching $2.6 million, driven by growth in pediatric revenue and increased disposable utilization. The company is focused on expanding the use of Aquadex into new clinical applications and has taken steps to reduce its monthly cash burn rate.

Nuwellis, Inc. reported a 17% increase in revenue for the third quarter of 2023 compared to the prior-year period. The growth was primarily driven by a 26% increase in circuit sales, reflecting increased therapy utilization. The company's net loss decreased compared to the prior year, and they are progressing with strategic collaborations.

Nuwellis, Inc. reported second-quarter 2023 financial results, featuring a revenue of $2.1 million, a gross margin of 55.3%, and a net loss of $4.8 million. The company highlighted a rebound in business, particularly in pediatrics, and a collaboration agreement with DaVita Inc.

Nuwellis, Inc. reported first quarter 2023 financial results with revenue of $1.8 million, a 5% decrease compared to the prior-year period. The heart failure segment saw growth, but pediatrics and critical care declined. The company had cash, cash equivalents, and marketable securities of $12.1 million and no debt as of March 31, 2023.

Nuwellis reported a 42% increase in revenue for Q4 2022, reaching $2.3 million, and a gross margin of 56.9%, up 250 basis points year-over-year. The company's net loss for the quarter was $1.9 million, which includes $2.6 million of Other Income related to the year-end revaluation of warrants.

Nuwellis reported an 11% increase in revenue compared to the same quarter last year, driven by strategic initiatives. The company's net loss decreased compared to the prior year, and cash and cash equivalents totaled $12.1 million at the end of the quarter.

Nuwellis, Inc. reported a total revenue of $2.2 million for Q2 2022, representing a 15% increase compared to the previous quarter. The company's net loss was $4.3 million, and cash and cash equivalents totaled $15.3 million as of June 30, 2022.

Nuwellis, Inc. announced its first quarter 2022 financial results, reporting total revenue of $1.9 million, which was even with the prior-year period and up 17% sequentially from the fourth quarter of 2021. The company's gross margin increased to 57.2%, and selling, general, and administrative expenses decreased by 16% compared to the prior-year period. The net loss for the quarter was $4.5 million, an improvement compared to the prior year.

Nuwellis, Inc. reported a revenue of $1.6 million for Q4 2021, a 19.6% decrease compared to the prior year period. The net loss for the quarter was $4.4 million, compared to a net loss of $3.1 million in the prior year period. The company ended the year with $24.2 million in cash and cash equivalents and no debt.

Nuwellis reported a slight decrease in revenue for Q3 2021 compared to the prior year, driven by COVID-19 impacts. However, gross margin increased due to favorable product mix, and the company opened new pediatric accounts. The company completed a capital raise of $10 million and ended the quarter with $28.4 million in cash.

Nuwellis, Inc. reported a record quarterly revenue of $2.5 million for the second quarter of 2021, a 35% increase compared to the prior year period. The company ended the quarter with $24.0 million in cash and no debt.

Nuwellis, Inc. reported a revenue of $1.9 million for Q1 2021, an 18% increase compared to the prior year period. The company's net loss was $5.2 million, and it ended the quarter with $27.9 million in cash and no debt.

CHF Solutions, Inc. reported a 49.5% increase in revenue for the fourth quarter of 2020, reaching $2 million. The company's gross margin also improved to 56.1%. The growth was driven by increased utilization in critical care and pediatric accounts. The net loss for the quarter was $3.1 million.

CHF Solutions reported a 52% increase in revenue for the third quarter of 2020, driven by increased utilization in pediatric accounts and the addition of six new pediatric hospital accounts. The company's gross margin decreased due to customer incentives for console upgrades and a higher mix of international distributor revenue. They also regained compliance with NASDAQ's minimum bid price requirement.

CHF Solutions, Inc. reported a revenue of $1.9 million for the second quarter ended June 30, 2020, representing an 11% increase compared to the same period last year and a 14% increase from the first quarter of 2020. The company ended the quarter with $7.8 million in cash and no debt.

CHF Solutions, Inc. reported a 34% increase in revenue for the first quarter of 2020 compared to the previous year, with revenue reaching $1.6 million. The company also obtained regulatory clearances for its Aquadex SmartFlow system and expanded its commercial presence in Europe.

CHF Solutions, Inc. reported a revenue of $1.4 million for the fourth quarter ended December 31, 2019, which is a decrease of 8.8 percent compared to Q4 2018. The company's net loss for the quarter was $4.448 million, and it ended the year with $1.3 million in cash and no debt.